These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 17955550

  • 1. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
    Wilson CJ, Robbins LJ, Murphy JM, Chang AB.
    Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
    [Abstract] [Full Text] [Related]

  • 2. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA, Hilton J, Jepson B, Smith L.
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [Abstract] [Full Text] [Related]

  • 3. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Intervention Trial Study Group.
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [Abstract] [Full Text] [Related]

  • 4. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, Mazzarella G, Raia V.
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [Abstract] [Full Text] [Related]

  • 5. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R, Elkins M.
    Cochrane Database Syst Rev; 2021 Mar 09; 3(3):CD007923. PubMed ID: 33686652
    [Abstract] [Full Text] [Related]

  • 6. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R, Elkins M.
    Cochrane Database Syst Rev; 2016 Jul 26; 7(7):CD007923. PubMed ID: 27457496
    [Abstract] [Full Text] [Related]

  • 7. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R, Elkins M.
    Cochrane Database Syst Rev; 2011 May 11; (5):CD007923. PubMed ID: 21563162
    [Abstract] [Full Text] [Related]

  • 8. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R, Elkins M.
    Cochrane Database Syst Rev; 2018 Nov 12; 11(11):CD007923. PubMed ID: 30480755
    [Abstract] [Full Text] [Related]

  • 9. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM, Volpi S, Salonini E, Müllinger B, Kroneberg P, Bakker M, Hop WC, Assael BM, Tiddens HA.
    Pediatr Pulmonol; 2014 Feb 12; 49(2):154-61. PubMed ID: 23913868
    [Abstract] [Full Text] [Related]

  • 10. Does the timing of inhaled dornase alfa matter?
    van der Giessen L.
    J Cyst Fibros; 2009 Jun 12; 8 Suppl 1():S6-9. PubMed ID: 19460684
    [Abstract] [Full Text] [Related]

  • 11. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R, Elkins M.
    Cochrane Database Syst Rev; 2013 Jun 05; (6):CD007923. PubMed ID: 23737088
    [Abstract] [Full Text] [Related]

  • 12. Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial.
    Bishop JR, Erskine OJ, Middleton PG.
    J Physiother; 2011 Jun 05; 57(4):223-9. PubMed ID: 22093120
    [Abstract] [Full Text] [Related]

  • 13. Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial.
    Mainz JG, Schiller I, Ritschel C, Mentzel HJ, Riethmüller J, Koitschev A, Schneider G, Beck JF, Wiedemann B.
    Auris Nasus Larynx; 2011 Apr 05; 38(2):220-7. PubMed ID: 21030168
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS, Chou W, Raimundo K, Trzaskoma B, Konstan MW.
    J Cyst Fibros; 2015 Nov 05; 14(6):777-83. PubMed ID: 25921451
    [Abstract] [Full Text] [Related]

  • 15. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K, Hamilton S, Johnson C.
    Chest; 1996 Oct 05; 110(4):889-95. PubMed ID: 8874241
    [Abstract] [Full Text] [Related]

  • 16. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.
    Suri R, Metcalfe C, Wallis C, Bush A.
    Respir Med; 2007 Feb 05; 101(2):254-60. PubMed ID: 16806875
    [Abstract] [Full Text] [Related]

  • 17. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.
    McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M.
    J Pediatr; 2008 Dec 05; 153(6):752-7. PubMed ID: 18760423
    [Abstract] [Full Text] [Related]

  • 18. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
    Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F.
    Eur Respir J; 2011 Apr 05; 37(4):806-12. PubMed ID: 20693248
    [Abstract] [Full Text] [Related]

  • 19. Dornase alfa in early cystic fibrosis lung disease.
    Robinson PJ.
    Pediatr Pulmonol; 2002 Sep 05; 34(3):237-41. PubMed ID: 12203856
    [Abstract] [Full Text] [Related]

  • 20. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
    Mainz JG, Schien C, Schiller I, Schädlich K, Koitschev A, Koitschev C, Riethmüller J, Graepler-Mainka U, Wiedemann B, Beck JF.
    J Cyst Fibros; 2014 Jul 05; 13(4):461-70. PubMed ID: 24594542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.